D&A
Becton, Dickinson and Company D&A decreased by 8.3% to $563.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.7%, from $567.00M to $563.00M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 2.9% CAGR.
Analysis
How to read this metric
High levels relative to revenue may indicate a capital-intensive business model with significant ongoing investment requirements.
Detailed definition
This represents the non-cash accounting allocation of the cost of tangible and intangible assets over their useful lives...
Peer comparison
Varies significantly by industry; medical device manufacturers typically have high levels due to specialized manufacturing equipment.
depreciation_and_amortization_cfHistorical Data
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $535.00M | $582.00M | $546.00M | $548.00M | $554.00M | $581.00M | $567.00M | $563.00M | $571.00M | $587.00M | $561.00M | $571.00M | $568.00M | $586.00M | $607.00M | $567.00M | $702.00M | $629.00M | $614.00M | $563.00M |
| QoQ Change | — | +8.8% | -6.2% | +0.4% | +1.1% | +4.9% | -2.4% | -0.7% | +1.4% | +2.8% | -4.4% | +1.8% | -0.5% | +3.2% | +3.6% | -6.6% | +23.8% | -10.4% | -2.4% | -8.3% |
| YoY Change | — | — | — | — | +3.6% | -0.2% | +3.8% | +2.7% | +3.1% | +1.0% | -1.1% | +1.4% | -0.5% | -0.2% | +8.2% | -0.7% | +23.6% | +7.3% | +1.2% | -0.7% |
Business Segments
| Segment | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Connected Care | — | — | — | — | — | — | — | $194.00M |
| Interventional | $196.50M | $196.50M | $200.00M | $198.00M | — | — | $197.00M | $192.00M |
| Medical Essentials | — | — | — | — | — | — | — | $147.00M |
| BioPharma Systems | — | — | — | — | — | — | — | $27.00M |
| Life Sciences | $68.00M | $68.00M | $44.00M | — | — | — | $45.00M | — |
| Medical | $304.00M | $304.00M | $348.25M | $348.25M | $348.25M | $348.25M | — | — |
| Total | $568.00M | $586.00M | $607.00M | $567.00M | $702.00M | $629.00M | $614.00M | $563.00M |
Medical is derived from annual filings.
Life Sciences was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's d&a?
- Becton, Dickinson and Company (BDX) reported d&a of $563.00M in Q1 2026.
- How has Becton, Dickinson and Company's d&a changed year-over-year?
- Becton, Dickinson and Company's d&a decreased by 0.7% year-over-year, from $567.00M to $563.00M.
- What is the long-term trend for Becton, Dickinson and Company's d&a?
- Over 4 years (2021 to 2025), Becton, Dickinson and Company's d&a has grown at a 2.9% compound annual growth rate (CAGR), from $2.23B to $2.51B.
- What does d&a mean?
- The non-cash expense representing the wear and tear or expiration of company assets.